Hepatokines mediate NAFLD impact on metabolic diseases and help to identify subtypes
German researchers from the University of Tübingen, Helmholtz Munich and the German Center for Diabetes Research, and Harvard Medical...
top of page
Browse by category
Search
Antibody candidate for treating serious liver disease
A study led by researchers from Karolinska Institutet has identified a drug candidate for the treatment of fatty liver. The preclinical...
Plenity induced weight loss results in NALFD fibrosis score improvement
A post-hoc analysis showed that treatment for weight management with Plenity decreased a marker for liver fibrosis (the NAFLD fibrosis...
Browse by tag
bottom of page